icon
icon
Overview

Male breast cancer develops when abnormal cells in the breast grow uncontrollably and form a malignant tumour. Although men have much less breast tissue than women, they still have breast ducts and can develop breast cancer.

Most male breast cancers begin in the ducts and are classified as invasive ductal carcinoma. Invasive lobular carcinoma is uncommon because the male breast normally contains few or no developed lobules. DCIS and other less common breast cancer types may also occur.

Most breast cancers in men are hormone receptor-positive. HER2-positive and triple-negative breast cancers can also develop, although they are less common. Treatment is based on the tumour's stage and biological features rather than the patient's sex alone.

Male breast cancer is sometimes diagnosed later because breast cancer may not be suspected when a man develops a breast lump or nipple change. Early evaluation of an unexplained breast abnormality is therefore important.

At Apollo Cancer Centres, male breast cancer care is planned by a multidisciplinary team that may include breast surgical oncologists, medical oncologists, radiation oncologists, radiologists, pathologists, genetic counsellors, reconstructive surgeons, and supportive-care professionals.

Risk Factors for Male Breast Cancer

The exact cause of most male breast cancers is unknown.
Factors associated with an increased risk may include:
Increasing Age

Increasing Age

Male breast cancer is most frequently diagnosed in older adults, although it can occur at any age.
Family History

Family History

Having close relatives with breast, ovarian, pancreatic, prostate, or related cancers may increase the risk.
Inherited Genetic Variants

Inherited Genetic Variants

Pathogenic variants in BRCA2 are particularly associated with male breast cancer. BRCA1, PALB2, CHEK2, ATM, TP53, PTEN, and other genes may also be relevant.
Klinefelter Syndrome

Klinefelter Syndrome

Men with this genetic condition have an additional X chromosome and higher estrogen levels, which increase breast cancer risk.
Previous Chest Radiation

Previous Chest Radiation

Radiation to the chest for another cancer can increase the later risk of breast cancer.
Liver Disease

Liver Disease

Severe liver disease may alter the balance between androgens and estrogens.
Testicular Conditions

Testicular Conditions

Undescended testicles, testicular injury, surgical removal of a testicle, or certain testicular disorders may affect hormone levels.
Estrogen Exposure

Estrogen Exposure

Treatment containing estrogen may increase risk, although the absolute risk remains low.
Excess Body Weight

Excess Body Weight

Fat tissue can increase the conversion of androgens into estrogens.
Limited Physical Activity

Limited Physical Activity

Low levels of regular activity may contribute to obesity and overall cancer risk.
Alcohol Consumption

Alcohol Consumption

Heavy alcohol use may increase risk directly and through its effects on the liver.
Increasing Breast Tissue

Increasing Breast Tissue

Gynecomastia is not itself considered a precancerous condition, but conditions that produce hormonal imbalance may be associated with both gynecomastia and increased breast cancer risk.
Most men with one or more risk factors do not develop breast cancer. Some patients have no identifiable risk factor other than age.

Male Breast Cancer Signs and Symptoms

Possible signs and symptoms include:

A painless lump or area of thickening, commonly beneath or close to the nipple

A lump that feels firm, irregular, or fixed

Swelling of part of the breast

Nipple inversion, flattening, or deviation

Bloody, clear, or other unexplained nipple discharge

Scaling, crusting, ulceration, or a persistent rash affecting the nipple or areola

Redness, puckering, dimpling, or thickening of the breast skin

An open sore on the breast or nipple that does not heal

Persistent pain or tenderness in the breast or nipple

A lump or swelling in the underarm

Enlarged lymph nodes near the collarbone

Changes affecting one breast that do not resolve

Persistent bone pain, breathlessness, cough, abdominal swelling, jaundice, weight loss, headaches, weakness, seizures, or other neurological symptoms if the cancer has spread

Most breast lumps in men are not cancerous and may be caused by gynecomastia, infection, cysts, fatty tissue, or another benign condition. However, a new one-sided lump, nipple discharge, nipple inversion, skin ulceration, or underarm swelling should be evaluated.

How Male Breast Cancer is Diagnosed

Diagnosis begins with a review of symptoms, medical history, previous radiation or hormone exposure, testicular and liver conditions, medication use, and family history. The doctor examines both breasts, nipples, underarms, and areas around the collarbones. Imaging is used to assess the abnormality, but a biopsy is required to confirm breast cancer.

• •

Mammography

Diagnostic mammography is commonly used to assess a suspicious breast lump in an adult man. It may show:

  • A mass or asymmetrical density

  • Irregular or spiculated margins

  • Suspicious calcifications

  • Skin or nipple changes

  • More than one abnormal area

  • Features suggesting gynecomastia or another benign condition

Mammography can help distinguish a suspicious mass from typical gynecomastia, but it cannot confirm cancer without a biopsy.

Breast Ultrasound

Ultrasound uses sound waves to examine the breast and underarm. It may help:

  • Determine whether an abnormality is solid or fluid-filled

  • Assess the size and characteristics of a mass

  • Examine tissue behind the nipple

  • Evaluate suspicious lymph nodes

  • Guide a core needle biopsy

For younger men with an indeterminate breast lump, ultrasound may be performed before mammography. The imaging approach is determined by the patient's age, examination findings, and level of clinical concern.

Breast MRI

Breast MRI is not routinely required for every man with suspected breast cancer. It may be considered to:

  • Assess the extent of a confirmed cancer

  • Examine possible involvement of the nipple, skin, or chest wall

  • Look for additional abnormalities

  • Evaluate response to treatment given before surgery

  • Investigate uncertain findings on mammography or ultrasound

  • Examine the opposite breast in selected high-risk situations

MRI findings may require additional imaging or biopsy because benign abnormalities can also enhance.

CT Scan

A CT scan of the chest, abdomen, or pelvis may be performed when the cancer is locally advanced, symptoms suggest distant spread, or the findings would influence treatment. Routine CT staging is generally not required for every small, apparently localised breast cancer.

PET-CT

PET-CT may be considered for selected patients with:

  • Locally advanced breast cancer

  • Suspicious lymph nodes outside the usual regional areas

  • Possible metastatic disease

  • Uncertain abnormalities on other imaging

  • Recurrent breast cancer

PET-CT does not replace biopsy when tissue confirmation of an accessible abnormality is required.

Bone Scan

A bone scan may be used if symptoms, blood-test abnormalities, or the extent of disease raise concern about cancer spreading to the bones. PET-CT, CT, or MRI may be used instead in selected situations.

Core Needle Biopsy

Core needle biopsy is the preferred method for diagnosing most male breast cancers. A hollow needle removes several tissue samples from the abnormal area, usually under ultrasound guidance.

The tissue allows the pathologist to:

  • Confirm whether cancer is present

  • Determine whether it is invasive

  • Identify the histological type

  • Assess tumour grade

  • Test for ER, PR, and HER2

  • Perform additional biomarker tests when indicated

Lymph-Node Biopsy

A suspicious underarm or regional lymph node may undergo fine-needle aspiration or core needle biopsy. Confirmation of lymph-node involvement can affect staging and determine whether systemic treatment should be given before surgery.

Surgical Biopsy

An incisional or excisional biopsy may occasionally be required when a needle biopsy is not possible or does not provide a conclusive diagnosis. Most suspicious male breast masses can be diagnosed using a core needle biopsy.

Laboratory

The biopsy tissue is examined by a specialist breast pathologist. Assessment may include:

  • Histopathology: Identifies whether the tumour is invasive ductal carcinoma, DCIS, or another breast cancer type.

  • Tumour grading: Assesses tubule formation, nuclear appearance, and mitotic activity to determine how abnormal and active the cancer cells appear.

  • Estrogen receptor testing: Determines whether estrogen may stimulate tumour growth and whether endocrine therapy may be beneficial.

  • Progesterone receptor testing: Provides additional information about hormone-receptor status and likely sensitivity to endocrine treatment.

  • HER2 testing: Uses immunohistochemistry and, when required, in-situ hybridisation to determine whether the cancer is HER2-positive.

  • Ki-67 assessment: May be performed in selected cases to estimate the proportion of actively dividing tumour cells.

  • Lymphovascular invasion: Determines whether cancer cells are present within small lymphatic or blood vessels near the tumour.

  • Margin assessment: Establishes whether invasive cancer or DCIS reaches the edge of the surgically removed tissue.

  • Lymph-node assessment: Determines the number of sampled lymph nodes and whether they contain cancer.

  • Treatment-response assessment: After preoperative systemic therapy, determines how much invasive cancer remains in the breast and regional lymph nodes.

  • Genomic assays: May be considered for selected hormone receptor-positive, HER2-negative early breast cancers when the result could help determine the likely benefit of chemotherapy. Evidence in men is less extensive, and results must be interpreted in the complete clinical context.

  • Germline genetic testing: Looks for inherited cancer-associated variants. Genetic testing should be offered or strongly considered for men diagnosed with breast cancer because the result may affect treatment, future cancer surveillance, and risk assessment for biological relatives.

Genetic testing may include BRCA1, BRCA2, PALB2, CHEK2, ATM, TP53, PTEN, and other genes selected according to the personal and family history. A pathogenic BRCA2 variant is particularly associated with male breast cancer and may also increase the risk of prostate, pancreatic, and other cancers.

Blood tests may include a complete blood count, kidney and liver function tests, blood chemistry, and other assessments needed before treatment. Blood tumour markers cannot diagnose early male breast cancer and are not used for routine screening.

Staging of Male Breast Cancer

Male breast cancer is staged using the same TNM and prognostic staging principles applied to breast cancer in women. The clinical stage is determined before definitive surgery using examination, imaging, and biopsy results. The pathological stage is determined after surgery by examining the removed breast tissue and lymph nodes.

  • Stage I: The cancer is small and confined to the breast or associated with only minimal regional lymph-node involvement.

  • Stage II: The cancer is larger or has spread to a limited number of nearby lymph nodes.

  • Stage III: The cancer involves more regional lymph nodes, the breast skin, or the chest wall without confirmed distant spread.

  • Stage IV: The cancer has spread to distant organs such as the bones, liver, lungs, brain, or distant lymph nodes.

When systemic treatment is given before surgery, the post-treatment stage describes the amount of cancer remaining in the breast and lymph nodes.

Stage alone does not determine treatment. Hormone-receptor status, HER2 status, tumour grade, genetic findings, response to preoperative therapy, age, general health, and patient preference are also considered.

Male Breast Cancer Male Breast Cancer

How Male Breast Cancer is Treated

• • •

Mastectomy

Mastectomy removes most or all breast tissue and is the most frequently performed operation for male breast cancer. It is commonly used because male breast tissue is limited and tumours often develop close to the nipple.

The operation may require removal of:

  • Breast tissue

  • The nipple and areola

  • Skin directly involved by the tumour

  • Tissue overlying the chest muscle

  • Part of the chest-wall muscle in uncommon cases of direct invasion

Breast-Conserving Surgery

Breast-conserving surgery removes the tumour with a rim of surrounding tissue while preserving the remaining breast.

It may be considered when:

  • The tumour is small relative to the available breast tissue

  • Clear surgical margins can be achieved

  • The nipple or extensive skin is not involved

  • An acceptable cosmetic result is possible

  • The patient can receive postoperative radiation therapy

Breast-conserving surgery is generally followed by radiation therapy. It is not unsuitable simply because the patient is male.

Sentinel Lymph-Node Biopsy

Sentinel lymph-node biopsy removes the first node or nodes most likely to receive drainage from the breast. It is commonly performed when the underarm lymph nodes do not appear to contain cancer. The procedure helps stage the cancer while limiting the extent of underarm surgery.

Axillary Lymph-Node Dissection

Axillary lymph-node dissection removes more lymph nodes from the underarm. It may be required when:

  • Several sentinel nodes contain cancer

  • Lymph-node involvement is confirmed before surgery

  • Significant nodal disease remains after preoperative treatment

  • Sentinel-node biopsy is unsuitable or unsuccessful

In selected cases, axillary radiation or more limited surgery may provide regional control while reducing the risk of lymphoedema, numbness, pain, and shoulder stiffness.

Endocrine Therapy

Most male breast cancers are estrogen receptor-positive. Tamoxifen is generally the preferred endocrine treatment for hormone receptor-positive breast cancer in men.

Tamoxifen may be recommended:

  • After surgery to reduce the risk of recurrence

  • Before surgery in selected patients

  • For locally advanced breast cancer

  • For recurrent or metastatic disease

Potential side effects include hot flushes, reduced sexual function, mood changes, weight change, fatigue, and blood clots. Side effects should be addressed actively because they can affect treatment adherence.

Aromatase Inhibitors

Aromatase inhibitors such as anastrozole, letrozole, or exemestane reduce estrogen production outside the testes. When used in men, they are generally combined with a gonadotropin-releasing hormone agonist or antagonist to suppress testicular hormone production. An aromatase inhibitor alone may not suppress estrogen adequately in men and is not routinely preferred over tamoxifen.

Other Endocrine and Targeted Treatment

For advanced hormone receptor-positive, HER2-negative breast cancer, treatment options may include:

  • Fulvestrant

  • CDK4/6 inhibitors

  • PI3K, AKT, or mTOR pathway inhibitors for appropriately selected tumours

  • Other endocrine-based combinations

The choice depends on previous treatment, genomic findings, disease extent, symptoms, and available approvals.

Chemotherapy

Chemotherapy may be recommended when:

  • The tumour has high-risk pathological features

  • Regional lymph nodes are involved

  • The cancer is hormone receptor-negative

  • The tumour is HER2-positive and chemotherapy is being combined with HER2-targeted therapy

  • The cancer is locally advanced

  • The cancer has spread or is progressing rapidly

  • Endocrine therapy is unlikely to provide adequate control

Chemotherapy may be given before surgery, after surgery, or for metastatic disease. The choice of regimen follows the same general principles used for breast cancer in women and is adjusted for age, cardiac health, kidney and liver function, previous treatment, and other medical conditions.

HER2-Targeted Therapy

HER2-positive male breast cancer is treated using HER2-directed approaches similar to those used for women.

Medicines may include:

  • Trastuzumab

  • Pertuzumab

  • Trastuzumab emtansine

  • Trastuzumab deruxtecan

  • Tucatinib

The choice depends on the stage, previous treatment, response to therapy, brain involvement, regulatory approval, and medicine availability. Cardiac function is assessed before and during selected HER2-targeted treatments.

PARP Inhibitors

A PARP inhibitor may be considered for an appropriately selected patient with a germline BRCA1 or BRCA2 pathogenic variant and HER2-negative breast cancer. Its use depends on whether the disease is early-stage or metastatic, previous treatment, regulatory approval, and current treatment guidelines.

Immunotherapy

Immunotherapy may be considered for selected patients with triple-negative metastatic breast cancer when the tumour meets the relevant biomarker criteria. It may also be used in certain high-risk early triple-negative cancers according to the treatment setting. Immune-checkpoint inhibitors are not routinely used for hormone receptor-positive breast cancer without another relevant indication.

Treatment of Metastatic Disease

Metastatic male breast cancer is generally managed using the same biological principles applied to metastatic breast cancer in women.

Treatment selection considers:

  • ER and PR status

  • HER2 status

  • Germline and tumour genetic findings

  • Previous treatment

  • Sites and extent of metastases

  • Symptoms and pace of progression

  • General health and organ function

  • Patient preferences and quality of life

Radiation After Breast-Conserving Surgery

Radiation therapy is generally recommended after breast-conserving surgery. It treats remaining breast tissue and reduces the risk of local recurrence. A focused additional dose may be delivered to the area where the tumour was removed.

Radiation After Mastectomy

Chest-wall radiation may be recommended when the risk of local recurrence is increased. Factors may include:

  • A large tumour

  • Skin, nipple, or chest-wall involvement

  • Positive or close surgical margins

  • Significant lymph-node involvement

  • Residual disease after preoperative treatment

Regional Nodal Radiation Therapy

Radiation may be directed to lymph-node regions near the breast when regional recurrence risk is increased. These may include the axillary, supraclavicular, or internal mammary lymph nodes.

Radiation for Advanced Disease

Radiation therapy may be used to:

  • Relieve pain from bone metastases

  • Treat or prevent spinal-cord compression

  • Control brain metastases

  • Reduce bleeding, ulceration, or pressure

  • Treat a symptomatic local recurrence

  • Control selected limited metastatic sites

Advanced techniques may include intensity-modulated radiation therapy, image-guided radiation therapy, stereotactic radiosurgery, or stereotactic body radiation therapy.

Chest-Wall Reconstruction

Most men do not require formal breast reconstruction after mastectomy. The operation is generally planned to produce a smooth chest contour and permit comfortable movement. Plastic or reconstructive surgery may be required when removal of a large tumour leaves a substantial skin or soft-tissue defect.

Nipple-Areola Reconstruction

Selected patients may consider nipple-areola reconstruction or medical tattooing after treatment. Suitability depends on the original tumour location, the surgery performed, radiation therapy, and personal preference.

Fat Grafting or Contour Correction

Fat grafting or scar revision may be considered after treatment to improve a chest-wall indentation, asymmetry, or contour irregularity. Any corrective procedure should be planned after confirming that cancer treatment is complete and the surgical area has healed.

Prognosis-for-Male-Breast-Cancer
Prognosis for Male Breast Cancer

The prognosis depends mainly on the stage and biological characteristics of the cancer. When compared at the same stage and with similar tumour features, treatment principles and outcomes can be broadly comparable to those for breast cancer in women.

Male breast cancer is sometimes diagnosed at a more advanced stage because early breast changes may be overlooked or attributed to a benign condition.

Factors that may influence prognosis include:
Stage at diagnosis
Tumour size
Number and location of involved lymph nodes
Presence or absence of distant metastases
Tumour grade
ER, PR, and HER2 status
Lymphovascular invasion
Response to preoperative systemic treatment
Whether clear surgical margins are achieved
Germline genetic findings
Ability to complete recommended treatment
Age, general health, and other medical conditions
Sites and extent of recurrent or metastatic disease

Regular follow-up is important because breast cancer can recur locally, regionally, or in distant organs. Follow-up may include clinical assessment, imaging of any remaining breast tissue, evaluation of treatment-related effects, and surveillance associated with an inherited genetic variant.

Why Choose ACC for Male Breast Cancer Treatment

Multidisciplinary care involving breast surgery, medical oncology, radiation oncology, radiology, pathology, genetics, and supportive care

Evaluation of male breast lumps and nipple changes using appropriate breast imaging and image-guided biopsy

Specialist breast pathology with ER, PR, HER2, and other biomarker testing

Personalised mastectomy or breast-conserving surgery when clinically appropriate

Sentinel lymph-node biopsy and tailored management of underarm lymph nodes

Endocrine therapy planned specifically for male physiology and hormone production

Chemotherapy, HER2-targeted therapy, immunotherapy, or other targeted medicines according to tumour biology

Advanced radiation techniques for breast, chest-wall, regional nodal, recurrent, or metastatic disease

Management of treatment effects, including hot flushes, sexual symptoms, and bone health

Chest-wall reconstruction, contour correction, and rehabilitation when required

Coordinated care for recurrent or metastatic breast cancer

Psychological support addressing body image, treatment adherence, sexuality, and survivorship

Risk information and genetic counselling for biological relatives when an inherited variant is identified
Frequently Asked Questions
01 Can men really develop breast cancer?
icon icon
Yes. Men have breast ducts and a small amount of breast tissue in which cancer can develop. Male breast cancer is uncommon, but any unexplained breast lump or nipple change should be assessed.
02 What is the most common sign of male breast cancer?
icon icon
The most common sign is a firm, usually painless lump beneath or close to the nipple. Nipple inversion, bloody discharge, skin ulceration, or an underarm lump may also occur.
03 How is male breast cancer different from gynecomastia?
icon icon
Gynecomastia is a benign enlargement of male breast tissue and often feels like a soft or rubbery disc beneath the nipple. Cancer is more likely to cause a hard, irregular, one-sided mass, but examination alone cannot always distinguish them. Imaging and biopsy may be required.
04 What is the most common type of breast cancer in men?
icon icon
Invasive ductal carcinoma is the most common type. Invasive lobular carcinoma is uncommon because men usually have very little developed lobular breast tissue.
05 Are most male breast cancers hormone receptor-positive?
icon icon
Yes. Most male breast cancers express estrogen receptors and may respond to endocrine therapy. Tamoxifen is generally the preferred endocrine treatment for men with hormone receptor-positive disease.
06 Does every man diagnosed with breast cancer need genetic testing?
icon icon
Genetic counselling and germline testing should be offered or strongly considered for men with breast cancer. An inherited variant may influence treatment, future cancer surveillance, and risk assessment for biological relatives.
07 Which inherited gene is most strongly associated with male breast cancer?
icon icon
BRCA2 is the gene most strongly associated with male breast cancer, although BRCA1, PALB2, CHEK2, ATM, TP53, PTEN, and other genes may also be relevant.
08 Does every man need a mastectomy?
icon icon
No. Mastectomy is common because male breast tissue is limited and tumours often develop close to the nipple. Breast-conserving surgery may still be possible when the tumour can be removed with clear margins and radiation therapy can be given.
09 Is treatment for male breast cancer the same as treatment for women?
icon icon
Treatment is guided by the same fundamental factors, including stage, hormone-receptor status, HER2 status, tumour grade, and genetic findings. Some aspects, particularly endocrine therapy and surgical planning, require consideration of male anatomy and hormone physiology.
10 Why is tamoxifen usually preferred over an aromatase inhibitor?
icon icon
Tamoxifen directly blocks the effect of estrogen on breast cancer cells. Aromatase inhibitors may not suppress estrogen adequately when used alone in men and are generally combined with medication that suppresses testicular hormone production.
11 Should the opposite breast be removed?
icon icon
Removal of the unaffected breast is not routinely required. It may be discussed in selected patients with a high-risk inherited genetic variant or another substantial risk factor. The potential benefits must be balanced against surgical complications and the individual's absolute risk.
12 Can male breast cancer return after treatment?
icon icon
Yes. It can recur in the chest wall, regional lymph nodes, or distant organs. The risk depends on the original stage, tumour biology, response to treatment, and completion of recommended therapy. Regular follow-up remains important.
image image
Book an Appointment
Please Enter Your Name
Please Enter Your Mobile Number
Please Enter OTP